Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Ahmet Aydin to Urinary Bladder Neoplasms

This is a "connection" page, showing publications Ahmet Aydin has written about Urinary Bladder Neoplasms.

 
Connection Strength
  
 
 
3.254
  
  1. Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):453.e19-453.e26.
    View in: PubMed
    Score: 0.753
  2. Aydin AM, Reich RR, Cao B, Cheriyan SK, Hajiran A, Zemp L, Yu A, Poch MA, Sexton WJ, Li R, Gilbert SM. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urol Oncol. 2022 04; 40(4):164.e1-164.e7.
    View in: PubMed
    Score: 0.715
  3. Aydin AM, Bunch BL, Beatty M, Hajiran A, Dhillon J, Sarnaik AA, Pilon-Thomas S, Poch MA. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Front Immunol. 2021; 12:628063.
    View in: PubMed
    Score: 0.685
  4. Aydin AM, Baydar DE, Hazir B, Babaoglu B, Bilen CY. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020 Oct; 38(10):2537-2545.
    View in: PubMed
    Score: 0.633
  5. Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer. 2020 12; 8(2).
    View in: PubMed
    Score: 0.169
  6. Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan; 205(1):100-108.
    View in: PubMed
    Score: 0.165
  7. Boegemann M, Aydin AM, Bagrodia A, Krabbe LM. Prospects and progress of immunotherapy for bladder cancer. Expert Opin Biol Ther. 2017 11; 17(11):1417-1431.
    View in: PubMed
    Score: 0.134
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.